Venus Remedies, a pharma company based in Chandigarh, India has obtained the European Union patent for its anti-infection product "Sulbactomax". This patent granted by European Patent Organisation (EPO) is India’s first researched anti-infection product to get EU patent and would cover the entire European Union including the United Kingdom, France, Germany, Italy, Spain, and Switzerland. This patent is valid till 2025 and will give Venus, patent access to 27 EU countries and 10 other European Countries.
Sulbactomax, an innovative product of Venus is competent enough to replace the ceftriaxone, the preferred anti-biotic till now. Sulbactomax is an antibiotic combination of Beta - lactam Ceftriaxone & Beta - lactamase for treating infections of the respiratory tract, acute bacterial otitis media, septicemia, pre- and post-operative infections, intra-abdominal infections and other infections caused by betalactamse producing ceftriaxone resistant bacterial strains.
Venus already has patent for Sulbactomax from South Africa and India and intends to enter the EU market through CTD (Common Technical Document) route and launch its product in market by 2013. At present Venus is marketing this product in India and seven other countries outside India.
(source:
http://www.itagbs.com/weekly_news.html)
